New AbbVie Subpopulation Data May Provide Edge Over Gilead In HCV Treatment
This article was originally published in The Pink Sheet Daily
Pharma may seek labeling update for 12 weeks of ribavirin-free therapy in genotype 1 patients with cirrhosis; Gilead’s label calls for 24 weeks of therapy.
You may also be interested in...
After most of the big pharmaceutical companies reported their full-year 2019 financial results, the second month of earnings season brings the long tail of smaller biotech companies and the generic pharmaceutical companies. There is more than one uncomfortable parallel from the former in the reports of the latter.
The HMA-EMA Big Data Task Force has offered recommendations to use data for the benefit of public health.